CN Patent

CN1210034C — 治疗银屑病的药物组合物

Assigned to Chongqing Huapont Pharm Co Ltd · Expires 2005-07-13 · 21y expired

What this patent protects

本发明提供了一种治疗银屑病的药物组合物，其制剂形式包括软膏剂和凝胶剂。该药物组合物含有0.05%～0.5%(w/w)他扎罗汀及0.05%～2.5%(w/w)肾上腺皮质激素类药物和其他药学上可接受的辅剂。所述肾上腺皮质激素类药物优选是二丙酸倍他米松。本发明药物组合物对银屑病有显著疗效，且安全性好。

USPTO Abstract

本发明提供了一种治疗银屑病的药物组合物，其制剂形式包括软膏剂和凝胶剂。该药物组合物含有0.05%～0.5%(w/w)他扎罗汀及0.05%～2.5%(w/w)肾上腺皮质激素类药物和其他药学上可接受的辅剂。所述肾上腺皮质激素类药物优选是二丙酸倍他米松。本发明药物组合物对银屑病有显著疗效，且安全性好。

Drugs covered by this patent

Patent Metadata

Patent number: CN1210034C
Jurisdiction: CN
Classification: —
Expires: 2005-07-13
Drug substance claim: No
Drug product claim: No
Assignee: Chongqing Huapont Pharm Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.